Single versus multiple fraction stereotactic radiosurgery for medium-sized brain metastases (4-14 cc in volume): reducing or fractionating the radiosurgery dose?

MRI brain metastases multiple fraction SRS radionecrosis recurrence response assessment single fraction SRS stereotactic radiosurgery

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 04 11 2023
accepted: 24 07 2024
medline: 28 8 2024
pubmed: 28 8 2024
entrez: 28 8 2024
Statut: epublish

Résumé

Stereotactic radiosurgery (SRS) of brain metastases (BM) and resection cavities is a widely used and effective treatment modality. Based on target lesion size and anatomical location, single fraction SRS (SF-SRS) or multiple fraction SRS (MF-SRS) are applied. Current clinical recommendations conditionally recommend either reduced dose SF-SRS or MF-SRS for medium-sized BM (2-2.9 cm in diameter). Despite excellent local control rates, SRS carries the risk of radionecrosis (RN). The purpose of this study was to assess the 12-months local control (LC) rate and 12-months RN rate of this specific patient population. This single-center retrospective study included 54 patients with medium-sized intact BM (n=28) or resection cavities (n=30) treated with either SF-SRS or MF-SRS. Follow-up MRI was used to determine LC and RN using a modification of the "Brain Tumor Reporting and Data System" (BT-RADS) scoring system. The 12-month LC rate following treatment of intact BM was 66.7% for SF-SRS and 60.0% for MF-SRS (p=1.000). For resection cavities, the 12-month LC rate was 92.9%% after SF-SRS and 46.2% after MF-SRS (p=0.013). For intact BM, RN rate was 17.6% for SF-SRS and 20.0% for MF-SRS (p=1.000). For resection cavities, RN rate was 28.6% for SF-SRS and 20.0% for MF-SRS (p=1.000). Patients with intact BM showed no statistically significant differences in 12-months LC and RN rate following SF-SRS or MF-SRS. In patients with resection cavities the 12-months LC rate was significantly better following SF-SRS, with no increase in the RNFS.

Sections du résumé

Background and purpose UNASSIGNED
Stereotactic radiosurgery (SRS) of brain metastases (BM) and resection cavities is a widely used and effective treatment modality. Based on target lesion size and anatomical location, single fraction SRS (SF-SRS) or multiple fraction SRS (MF-SRS) are applied. Current clinical recommendations conditionally recommend either reduced dose SF-SRS or MF-SRS for medium-sized BM (2-2.9 cm in diameter). Despite excellent local control rates, SRS carries the risk of radionecrosis (RN). The purpose of this study was to assess the 12-months local control (LC) rate and 12-months RN rate of this specific patient population.
Materials and methods UNASSIGNED
This single-center retrospective study included 54 patients with medium-sized intact BM (n=28) or resection cavities (n=30) treated with either SF-SRS or MF-SRS. Follow-up MRI was used to determine LC and RN using a modification of the "Brain Tumor Reporting and Data System" (BT-RADS) scoring system.
Results UNASSIGNED
The 12-month LC rate following treatment of intact BM was 66.7% for SF-SRS and 60.0% for MF-SRS (p=1.000). For resection cavities, the 12-month LC rate was 92.9%% after SF-SRS and 46.2% after MF-SRS (p=0.013). For intact BM, RN rate was 17.6% for SF-SRS and 20.0% for MF-SRS (p=1.000). For resection cavities, RN rate was 28.6% for SF-SRS and 20.0% for MF-SRS (p=1.000).
Conclusion UNASSIGNED
Patients with intact BM showed no statistically significant differences in 12-months LC and RN rate following SF-SRS or MF-SRS. In patients with resection cavities the 12-months LC rate was significantly better following SF-SRS, with no increase in the RNFS.

Identifiants

pubmed: 39193387
doi: 10.3389/fonc.2024.1333245
pmc: PMC11347337
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1333245

Informations de copyright

Copyright © 2024 Reinhardt, Ahmadli, Uysal, Shrestha, Schucht, Hakim and Ermiş.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Philipp Reinhardt (P)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Uzeyir Ahmadli (U)

University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.

Emre Uysal (E)

Department of Radiation Oncology, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Türkiye.

Binaya Kumar Shrestha (BK)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Philippe Schucht (P)

Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Arsany Hakim (A)

Department of Radiation Oncology, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Türkiye.

Ekin Ermiş (E)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Classifications MeSH